3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Head and Neck Neoplasms
121
Lung Neoplasms
119
Glioblastoma
118
Carcinoma, Non-Small-Cell Lung
118
Breast Neoplasms
105
Lymphoma
102
Squamous Cell Carcinoma of Head and Neck
90
Central Nervous System Neoplasms
83
Prostatic Neoplasms
80
Leukemia
77
Pancreatic Neoplasms
67
Gliosarcoma
66
Rectal Neoplasms
63
Precursor Cell Lymphoblastic Leukemia-Lymphoma
63
Esophageal Neoplasms
63
Brain Neoplasms
59
Lymphoma, Large B-Cell, Diffuse
56
Lymphoma, Follicular
55
Lymphoma, Non-Hodgkin
49
Hodgkin Disease
48
Burkitt Lymphoma
46
Sarcoma
43
Lymphoma, Large-Cell, Immunoblastic
42
Leukemia, Lymphocytic, Chronic, B-Cell
42
Myelodysplastic Syndromes
37
Lymphoma, Mantle-Cell
36
Glioma
36
Neoplasms
34
Astrocytoma
34
Lymphoma, B-Cell, Marginal Zone
33
Interventions
pertuzumab
1
pazopanib
1
daratumumab
1
Trastuzumab
1
Surgical Procedures, Operative
1
Sunitinib
1
Sorafenib
1
Risk Assessment
1
Radiotherapy
1
Injections, Subcutaneous
1
Focus Groups
1
Bandages, Hydrocolloid
1
Ado-Trastuzumab Emtansine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Patient Preference
×
Radiotherapy
×
Clear all
NCT05415215
2026-02-10
ProHer
Hoffmann-La Roche
Phase 3
Completed
346 enrolled
20 charts